Trial Profile
The Use of Peri-Operative Intravenous Estrogen for the Mitigation of Ischemia Reperfusion Injury in the Setting of Renal Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Conjugated estrogens (Primary)
- Indications Perioperative ischaemia; Reperfusion injury
- Focus Therapeutic Use
- Acronyms PERT
- 21 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Sep 2022 Planned End Date changed from 31 Jan 2022 to 31 Jan 2025.
- 06 Sep 2022 Planned primary completion date changed from 31 Jan 2022 to 31 Jan 2025.